Day One Biopharmaceuticals Inc (NASDAQ: DAWN) stock fell -0.16% on Monday to $12.12 against a previous-day closing price of $12.14. With 0.52 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.83 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $12.45 whereas the lowest price it dropped to was $12.03. The 52-week range on DAWN shows that it touched its highest point at $25.77 and its lowest point at $9.67 during that stretch. It currently has a 1-year price target of $37.78. Beta for the stock currently stands at -1.70.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DAWN was up-trending over the past week, with a rise of 6.41%, but this was up by 25.21% over a month. Three-month performance dropped to -11.73% while six-month performance fell -8.67%. The stock lost -42.53% in the past year, while it has lost -43.68% so far this year. A look at the trailing 12-month EPS for DAWN yields -2.28 with Next year EPS estimates of -2.28. For the next quarter, that number is -0.57. This implies an EPS growth rate of -4.90% for this year and -0.12% for next year.
Float and Shares Shorts:
At present, 73.46 million DAWN shares are outstanding with a float of 56.56 million shares on hand for trading. On Oct 30, 2023, short shares totaled 11.84 million, which was 13.60% higher than short shares on Sep 28, 2023. In addition to Dr. Jeremy Bender M.B.A., Ph.D. as the firm’s CEO, President & Director, Dr. Samuel C. Blackman M.D., Ph.D. serves as its Co-Founder and Head of R&D.
Through their ownership of 72.75% of DAWN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.11% of DAWN, in contrast to 42.29% held by mutual funds. Shares owned by individuals account for 31.22%. As the largest shareholder in DAWN with 8.98% of the stake, RA Capital Management LP holds 7,809,852 shares worth 7,809,852. A second-largest stockholder of DAWN, The Vanguard Group, Inc., holds 4,476,093 shares, controlling over 5.15% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in DAWN, holding 4,281,078 shares or 4.92% stake. With a 2.36% stake in DAWN, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 2,054,266 shares are owned by the mutual fund manager. The FTIF SICAV – Biotechnology Discov, which owns about 2.24% of DAWN stock, is the second-largest Mutual Fund holder. It holds 1,947,588 shares valued at 23.04 million. Vanguard Total Stock Market ETF holds 2.22% of the stake in DAWN, owning 1,932,967 shares worth 22.87 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DAWN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DAWN analysts setting a high price target of $50.00 and a low target of $10.00, the average target price over the next 12 months is $37.78. Based on these targets, DAWN could surge 312.54% to reach the target high and fall by -17.49% to reach the target low. Reaching the average price target will result in a growth of 211.72% from current levels.
Summary of Insider Activity:
Insiders traded DAWN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 24 while that of sell transactions has risen to 37 over the past year. The total number of shares bought during that period was 1,623,452 while 1,630,962 shares were sold.